<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Remogliflozin etabonate (RE), an inhibitor of the <z:chebi fb="199" ids="26708">sodium</z:chebi>-<z:chebi fb="105" ids="17234">glucose</z:chebi> transporter 2, improves <z:chebi fb="105" ids="17234">glucose</z:chebi> profiles in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>This study assessed safety, tolerability, pharmacokinetics, and pharmacodynamics of RE in subjects with type 1 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>RESEARCH DESIGN AND METHODS: Ten subjects managed with continuous subcutaneous insulin infusion were enrolled </plain></SENT>
<SENT sid="3" pm="."><plain>In addition to basal insulin, subjects received five randomized treatments: placebo, prandial insulin, 50 mg RE, 150 mg RE, and mg RE 500 </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Adverse events and incidence of <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> with RE did not differ from placebo and prandial insulin groups </plain></SENT>
<SENT sid="5" pm="."><plain>RE significantly increased urine <z:chebi fb="105" ids="17234">glucose</z:chebi> excretion and reduced the rise in plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> concentration after oral <z:chebi fb="105" ids="17234">glucose</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>RE reduced incremental adjusted weighted mean <z:chebi fb="105" ids="17234">glucose</z:chebi> (0-4 h) values by 42-49 mg/dL and mean <z:chebi fb="105" ids="17234">glucose</z:chebi> (0-10 h) by 52-69 mg/dL </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: RE can be safely administered with insulin in type 1 <z:mp ids='MP_0002055'>diabetes</z:mp> and reduces plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> concentrations compared with placebo </plain></SENT>
</text></document>